

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinopharm Tech Holdings Limited**

**國藥科技股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8156)**

### **(1) RESIGNATION OF EXECUTIVE DIRECTOR, GROUP CHIEF FINANCIAL OFFICER AND COMPLIANCE OFFICER; AND (2) CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE**

The Board hereby announces that Mr. HO Kam Kin has resigned as the executive Director, Group chief financial officer, compliance officer, Company Secretary and Authorised Representative with effect from 13 June 2025.

Following Mr. HO's resignation, Ms. WONG Chi Ling has been appointed as the Company Secretary and Mr. CHIU Sin Nang Kenny, an executive Director, has been appointed as the Authorised Representative, both with effect from 13 June 2025.

#### **RESIGNATION OF EXECUTIVE DIRECTOR, GROUP CHIEF FINANCIAL OFFICER AND COMPLIANCE OFFICER**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), hereby announces that with effect from 13 June 2025, Mr. HO Kam Kin (“**Mr. HO**”) has resigned as an executive Director, Group chief financial officer and compliance officer of the Company due to his other personal engagements.

Mr. HO has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

## **CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE**

The Board further announces that Mr. HO has resigned as the company secretary of the Company (the “**Company Secretary**”), the authorised representative (the “**Authorised Representative**”) with effect from 13 June 2025.

Following Mr. HO’s resignation, Ms. WONG Chi Ling (“**Ms. WONG**”) has been appointed as the Company Secretary pursuant to Rule 5.14 of The Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited with effect from 13 June 2025 and Mr. CHIU Sin Nang Kenny, an executive Director, has been appointed as the Authorised Representative pursuant to Rule 5.24 of the GEM Listing Rules with effect from 13 June 2025.

Ms. WONG possesses over 25 years of experience in finance, accounting and company secretarial services experience in Hong Kong. She obtained a master’s degree of arts in parent education and a professional diploma in guidance and counselling from The Chinese University of Hong Kong, a postgraduate diploma in early childhood education from The Hong Kong Baptist University and a bachelor’s degree of arts in accountancy from the Hong Kong Polytechnic University. Ms. WONG is a fellow member of The Association of Chartered Certified Accountants in the United Kingdom, a fellow member of The Institute of Chartered Accountants in England and Wales and an associate member of Institute of Certified Public Accountants.

The Board would like to take this opportunity to express its appreciation and gratitude to Mr. HO for his valuable contributions to the Company during his tenure of office and also extends its welcome to Ms. WONG on her new appointment.

By order of the Board  
**Sinopharm Tech Holdings Limited**  
國藥科技股份有限公司  
**KWOK Shuk Yi**  
*Executive Director*

Hong Kong, 13 June 2025

*As at the date of this announcement, the Board comprises Mr. CHIU Sin Nang Kenny, and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.*